INNODIA: A Collaborative Approach to Understanding and Preventing Type 1 Diabetes
One year ago, INNODIA formed as a collaborative effort towards delaying and preventing type 1 diabetes (T1D).
This European-based consortium brings together patients and clinical researchers and is creating a living biobank to better understand T1D and its causes. Researchers in the network are looking at biomarkers to examine why some people develop the disease and their family members don’t.
Helmsley is a supporting member of INNODIA alongside major T1D stakeholders including the Innovative Medicines Initiative (IMI), the European Federation of Pharmaceutical Industries and Association (EFPIA), 26 academic institutions and clinics, and JDRF.
In a new video from INNODIA’s first annual meeting, T1D Program Director Gina Agiostratidou and other leaders discuss their vision to accelerate prevention therapies.